1.4675 0.018 (1.21%) | 04-23 13:03 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 1-year : | ||
Resists | First : | Second : | ||
Pivot price | ||||
Supports | First : | Second : | ||
MAs | MA(5) : | MA(20) : | ||
MA(100) : | MA(250) : | |||
MACD | MACD : | Signal : | ||
%K %D | K(14,3) : | D(3) : | ||
RSI | RSI(14): | |||
52-week | High : | Low : |
If tomorrow: | Open lower | Open higher |
High: | - | - |
Low: | - | - |
Close: | - | - |
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Mon, 13 Jan 2020
Interpace Biosciences Enters into Agreement for $20 Million Investment from 1315 Capital and Ampersand Capital ... - GlobeNewswire
Wed, 23 Dec 2015
PDI Completes Sale, Changes Name to Interpace Diagnostics Group - BioSpace
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
PNK
|
|
Sector:
Healthcare
|
|
Industry:
Medical - Diagnostics & Research
|
|
Shares Out | 0 (M) |
Shares Float | 0 (M) |
Held by Insiders | (%) |
Held by Institutions | (%) |
Shares Short | 0 (K) |
Shares Short P.Month | 0 (K) |
EPS | |
EPS Est Next Qtrly | |
EPS Est This Year | |
EPS Est Next Year | |
Book Value (p.s.) | |
Profit Margin | % |
Operating Margin | % |
Return on Assets (ttm) | % |
Return on Equity (ttm) | % |
Qtrly Rev. Growth | % |
Gross Profit (p.s.) | |
Sales Per Share | |
EBITDA (p.s.) | |
Qtrly Earnings Growth | % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | |
PEG Ratio | |
Price to Book value | |
Price to Sales | |
Price to Cash Flow |
Dividend | |
Forward Dividend | |
Dividend Yield | 0% |
Dividend Pay Date | |
Ex-Dividend Date |